Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial
| dc.contributor.author | Rockers, Peter C | |
| dc.contributor.author | Laing, Richard O | |
| dc.contributor.author | Ashigbie, Paul G | |
| dc.date.accessioned | 2021-07-02T10:49:35Z | |
| dc.date.available | 2021-07-02T10:49:35Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme.Methods We did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned to the intervention or the control group with a covariate-constrained randomisation procedure that maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095). | en_US |
| dc.identifier.citation | Rockers et al. (2019). Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial. The Lancet Global Health, 7(4), e492–e502. https://doi.org/10.1016/S2214-109X(18)30563-1 | en_US |
| dc.identifier.issn | 2214-109X | |
| dc.identifier.uri | http://hdl.handle.net/10566/6353 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Non-communicable diseases | en_US |
| dc.subject | Kenya | en_US |
| dc.subject | Medicines use | en_US |
| dc.title | Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial | en_US |
| dc.type | Article | en_US |